Phaseline

Companies › Medigen Vaccine Biologics

Medigen Vaccine Biologics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Vaccines.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Envacgen®
EV71 vaccine
–Phase 3Enterovirus 71 Inactivated Vaccine–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07178522Envacgen®Phase 3Enterovirus 71 Inactivated VaccineVaccinesJul 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Beijing Minhai Biotechnology Sinovac (Dalian) Vaccine Technology BioNet-Asia Aribio Lab Cellid

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.